Studies have demonstrated that patients with high-risk cytogenetics can achieve MRD- and that this depth of response is associated with improved rates of OS and PFS, similar to standard-risk populations. Data support that MRD- can be used to inform treatment decisions regardless of a patient’s risk profile or disease stage.